PANAGENE,  World's First Development of Thyroid Cancer Related Gene Diagnosis kit

PANAGENE Inc., a company that specializes in gene diagnosis based on PNA (Peptide Nucleic Acid; an artificial nucleotide), announced on July 7 that it has succeeded in developing Telomerase reverse transcriptase promoter (TERT) and Iran TERT mutation diagnostic kit using PNA.

TERT is the most accurate indicator of the risk of recurrence of papillary thyroid cancer in the US Thyroid Society in 2015. Since then, studies that predict the prognosis and the risk of metastasis in some brain tumor patients, as well as thyroid cancer, have become one of the most important genes worldwide.

However, due to the inherent characteristics of TERT, it was difficult to apply it to actual clinical field.

 

The DNA mutation test using the DNA amplification method called PCR (Polymerase Chain Reaction) is used for the mutation test. However, since the TERT mutation test results in a drop in the PCR efficiency due to the base sequence characteristic of TERT alone, The biggest problem was that there were many cases that could not be done.

PANAGENE has developed a diagnostic kit that overcomes these problems using the proprietary features and advantages of PNA, and its proprietary PNAClamp ™ platform technology. The PANAGENE product is the world's first TERT diagnostic kit using real-time PCR.

"We will begin the process of registering a food and drug safety office so that the TERT diagnostic kit can be used in the medical field in a short period of time." said.

For the original article, please click the following link.

http://news.mk.co.kr/newsRead.php?year=2017&no=600385

- PANAGENE, Inc. -